AI Article Synopsis
- Paclitaxel (PTX) is a common drug used to treat prostate cancer, but it faces challenges like poor solubility, lack of targeted action, and side effects.
- This study introduces a new formulation called a paclitaxel-ginsenoside polymeric micelle (RPM), which aims to improve PTX's effectiveness while reducing toxicity.
- The RPM utilizes the dual benefits of ginsenoside Rg5 to enhance water solubility and target cancer cells more effectively, while also providing anti-inflammatory and neuroprotective benefits for potential clinical use.
Article Abstract
Paclitaxel (PTX) is one of the first-line drugs for prostate cancer (PC) treatment. However, the poor water solubility, inadequate specific targeting ability, multidrug resistance, and severe neurotoxicity are far from being fully resolved, despite diverse PTX formulations in the market, such as the gold-standard PTX albumin nanoparticle (Abraxane) and polymer micelles (Genexol-PM). Some studies attempting to solve the multiple problems of chemotherapy delivery fall into the trap of an extremely complicated formulation design and sacrifice druggability. To better address these issues, this study designed an efficient, toxicity-reduced paclitaxel-ginsenoside polymeric micelle (RPM). With the aid of the inherent amphiphilic molecular structure and pharmacological effects of ginsenoside Rg5, the prepared RPM enhances the water solubility and active targeting of PTX, inhibiting chemotherapy resistance in cancer cells. Moreover, the polymeric micelles demonstrated favorable anti-inflammatory and neuroprotective effects, providing ideas for the development of new clinical anti-PC preparations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.molpharmaceut.4c00204 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mechanism of action of protopanaxadiol ginsenosides on hepatocellular carcinoma and network pharmacological analysis.
Chin Herb Med
October 2024
College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China.
Article Synopsis
- * Ginsenosides like Rb, Rd, Rg, and Rh show anti-inflammatory and anti-tumor effects, and research indicates PDs can inhibit HCC development by targeting multiple signaling pathways.
- * This review explores the anti-HCC effects of PDs, their mechanisms, and highlights the necessity for further studies to optimize PDs for safe and effective clinical use.
Ginsenoside Rg5, a potent agonist of Nrf2, inhibits HSV-1 infection-induced neuroinflammation by inhibiting oxidative stress and NF-κB activation.
J Ginseng Res
July 2024
Korean Medicine Application Center, Korea Institute of Oriental Medicine (KIOM), Dong-gu, Daegu, Republic of Korea.
Article Synopsis
- * The study explored ginsenoside Rg5, which activates the Nrf2 pathway, and found that it inhibited HSV-1 replication by reducing ROS and inflammatory responses in infected host cells.
- * These results indicate that ginsenoside Rg5 could be a potential new treatment for HSV-1 infections and related neuroinflammation.
Study on the anti-skin aging effect and mechanism of Sijunzi Tang based on network pharmacology and experimental validation.
J Ethnopharmacol
October 2024
Skin Health and Cosmetic Development & Evaluation Laboratory, China Pharmaceutical University, Nanjing, 211198, Jiangsu, China. Electronic address:
Article Synopsis
- - SJZT is a traditional Chinese medicine formula made from four herbs known for its ability to enhance spleen function and combat skin aging, but its specific mechanisms are not yet fully understood
- - The study aims to investigate SJZT's effects on skin aging using network pharmacology to find its possible therapeutic mechanisms and validate them through lab experiments
- - Results showed that specific proteins related to skin aging and key active components of SJZT, like glycyrrhizin and ginsenoside, could effectively target cellular processes involved in senescence
Self-Assembled Micelles Based on Ginsenoside Rg5 for the Targeted Treatment of PTX-Resistant Tumors.
Mol Pharm
July 2024
Medical Research Institute, College of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China.
Article Synopsis
- Paclitaxel (PTX) is a common drug used to treat prostate cancer, but it faces challenges like poor solubility, lack of targeted action, and side effects.
- This study introduces a new formulation called a paclitaxel-ginsenoside polymeric micelle (RPM), which aims to improve PTX's effectiveness while reducing toxicity.
- The RPM utilizes the dual benefits of ginsenoside Rg5 to enhance water solubility and target cancer cells more effectively, while also providing anti-inflammatory and neuroprotective benefits for potential clinical use.
Exploring the pathways of drug repurposing and Panax ginseng treatment mechanisms in chronic heart failure: a disease module analysis perspective.
Sci Rep
May 2024
Department of Education, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Chronic Heart Failure (CHF) is a significant global public health issue, with high mortality and morbidity rates and associated costs. Disease modules, which are collections of disease-related genes, offer an effective approach to understanding diseases from a biological network perspective. We employed the multi-Steiner tree algorithm within the NeDRex platform to extract CHF disease modules, and subsequently utilized the Trustrank algorithm to rank potential drugs for repurposing.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!